Clinical risk stratification: Prague validation of the DAAE score, a clinical tool for estimating risk of disesase progression in multiple sclerosis

IF 2.9 3区医学 Q2 CLINICAL NEUROLOGY

Multiple sclerosis and related disorders Pub Date : 2025-04-07 DOI:10.1016/j.msard.2025.106423

Julia R. Jelgerhuis , Tomas Uher , Eva Kubala Havrdova , Dana Horakova , Menno M. Schoonheim , Tom A. Fuchs

{"title":"Clinical risk stratification: Prague validation of the DAAE score, a clinical tool for estimating risk of disesase progression in multiple sclerosis","authors":"Julia R. Jelgerhuis , Tomas Uher , Eva Kubala Havrdova , Dana Horakova , Menno M. Schoonheim , Tom A. Fuchs","doi":"10.1016/j.msard.2025.106423","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Secondary progressive MS is associated with a worse prognosis, warranting the need for early predictive tools. The DAAE score estimates the five-year risk of transition to clinical diagnosis of SPMS, showing a 38 % risk in high-risk patients in Amsterdam and Buffalo data. The DAAE score remains to be validated against objective disease progression criteria.</div></div><div><h3>Methods</h3><div>External validation using data from the Prague MS cohort and MSBase-Lorscheider criteria.</div></div><div><h3>Results</h3><div>Among 2022 patients from the Prague MS database, 14.3 % clinically progressed according to MSbase-Lorscheider criteria over five years. Risk increased with higher DAAE scores comparable to the Amsterdam and Buffalo data; secondary validation showed an AUROC of 0.742 with faster progression for higher risk groups (<em>p</em> < 0.05), therapy-adjusted.</div></div><div><h3>Conclusion</h3><div>The DAAE score performs similarly between centers and using objective criteria. These validation steps support its use in personalized MS management and treatment.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"98 ","pages":"Article 106423"},"PeriodicalIF":2.9000,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple sclerosis and related disorders","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2211034825001658","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Secondary progressive MS is associated with a worse prognosis, warranting the need for early predictive tools. The DAAE score estimates the five-year risk of transition to clinical diagnosis of SPMS, showing a 38 % risk in high-risk patients in Amsterdam and Buffalo data. The DAAE score remains to be validated against objective disease progression criteria.

Methods

External validation using data from the Prague MS cohort and MSBase-Lorscheider criteria.

Results

Among 2022 patients from the Prague MS database, 14.3 % clinically progressed according to MSbase-Lorscheider criteria over five years. Risk increased with higher DAAE scores comparable to the Amsterdam and Buffalo data; secondary validation showed an AUROC of 0.742 with faster progression for higher risk groups (p < 0.05), therapy-adjusted.

Conclusion

The DAAE score performs similarly between centers and using objective criteria. These validation steps support its use in personalized MS management and treatment.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Multiple sclerosis and related disorders CLINICAL NEUROLOGY-

CiteScore

5.80

自引率

20.00%

发文量

814

审稿时长

66 days

期刊介绍： Multiple Sclerosis is an area of ever expanding research and escalating publications. Multiple Sclerosis and Related Disorders is a wide ranging international journal supported by key researchers from all neuroscience domains that focus on MS and associated disease of the central nervous system. The primary aim of this new journal is the rapid publication of high quality original research in the field. Important secondary aims will be timely updates and editorials on important scientific and clinical care advances, controversies in the field, and invited opinion articles from current thought leaders on topical issues. One section of the journal will focus on teaching, written to enhance the practice of community and academic neurologists involved in the care of MS patients. Summaries of key articles written for a lay audience will be provided as an on-line resource. A team of four chief editors is supported by leading section editors who will commission and appraise original and review articles concerning: clinical neurology, neuroimaging, neuropathology, neuroepidemiology, therapeutics, genetics / transcriptomics, experimental models, neuroimmunology, biomarkers, neuropsychology, neurorehabilitation, measurement scales, teaching, neuroethics and lay communication.